A primary care focus on the diagnosis and treatment of major depressive disorder in adults

Journal of Psychiatric Practice

Volumn 17, Issue 5, 2011, Pages 340-350

  Halaris, Angelos ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

antidepressant; cost; major depressive disorder; non pharmacologic treatment; patient adherence; symptom remission; tolerability; treatment selection

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; ISOCARBOXAZID; MAPLAND; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NARDIN; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SELEGILINE; SEROTONIN DOPAMINE REUPTAKE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ADULT; ARTICLE; BLOOD PRESSURE; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; COGNITIVE THERAPY; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; FLUSHING; FOOD; FOOD DRUG INTERACTION; HEALTH CARE COST; HEART ARRHYTHMIA; HEART RATE; HUMAN; MAJOR DEPRESSION; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT PREFERENCE; PERSONALIZED MEDICINE; PHOTOTHERAPY; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RECURRENT DISEASE; REMISSION; SCREENING; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; URINE RETENTION; VAGUS NERVE STIMULATION; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; UNITED STATES;

EID: 80053064737     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000405364.90043.bd     Document Type: Article

References (75)

1. Department of Veterans Affairs, Department of Defense. VA/DoD clinical practice guideline for management of major depressive disorder (MDD). Washington, DC Department of Veterans Affairs, Department of Defense; 2009 (available at www.healthquality.va.gov/mdd/mdd-full09-c.pdf, last updated, May 2009, accessed July 25, 2011).
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289 3095-105. (Pubitemid 37432885)
3. Unützer J, Katon W, Callahan CM, et al. Improving mood-promoting access to collaborative treatment. Collaborative care management of late-life depression in the primary care setting A randomized controlled trial. JAMA 2002; 288 2836-45. (Pubitemid 35425069)
4. National Institute of Mental Health. The numbers count Mental disorders in America, 2009 (available at www.apps.nimh.nih.gov/health/publications/the- numbers-count-mental-disorders-in-america.shtml, accessed August 23, 2011).
5. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and co-morbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62 617-27. (Pubitemid 40973437)
6. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder Results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005;62 1097-106. (Pubitemid 41396935)
7. American Foundation for Suicide Prevention. Facts and figures National statistics 2009 (available at www.afsp.org/index.cfm?fuseaction=home. viewpage&page-id=050fea9f-b064-4092-b1135c3a70de1fda, accessed July 25, 2011).
8. Falagas ME, Zarkadoulia EA, Ioannidou EN, et al. The effect of psychosocial factors on breast cancer outcome A systematic review. Breast Cancer Res 2007; 9 R44.
9. Kimmel PL, Peterson RA, Weihs KL, et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000; 57 2093-8. (Pubitemid 30252302)
10. Verhagen M, van der Meij A, Franke B, et al. Familiality of major depressive disorder and gender differences in comorbidity. Acta Psychiatr Scand 2008;18 130-8. (Pubitemid 351962159)
11. Davis L, Uezato A, Newell JM, et al. Major depression and comorbid substance use disorders. Curr Opin Psychiatry 2008; 21 14-8. (Pubitemid 351339802)
12. Nuyen J, Schellevis FG, Satariano WA, et al. Comorbidity was associated with neurologic and psychiatric diseases A general practice-based controlled study. J Clin Epidemiol 2006; 59 1274-84. (Pubitemid 44708605)
13. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64 327-37. (Pubitemid 46376789)
14. Moreno FA, Heninger GR, McGahuey CA, et al. Tryptophan depletion and risk of depression relapse A prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry 2000; 48 327-9. (Pubitemid 30645805)
15. Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans A meta-analysis of monoamine depletion studies. Mol Psychiatry 2007;2 331-59. (Pubitemid 46496835)
16. Pariante CM. Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and gluco-corticoids. Ann NY Acad Sci 2009;1179 144-52.
17. Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res 2010;3 56-73.
18. Kendler KS, Gatz M, Gardner CO, et al. A Swedish national twin study of lifetime major depression. Am J Psychiatry 2006;163 109-14. (Pubitemid 43050111)
19. Edvardsen J, Torgersen S, Røysamb E, et al. Unipolar depressive disorders have a common genotype. J Affect Disord 2009;117 30-41
20. U.S. Preventive Services Task Force. Screening for depression in adults U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;151 784-92.
21. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC American Psychiatric Association; 2000.
22. American Psychiatric Association. DSM-5 development Depressive disorders (available at www.dsm5.org/ProposedRevision/Pages/DepressiveDisorders.aspx, accessed July 25, 2011).
23. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4 561-71.
24. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety Psychometric properties. J Consult Clin Psychol 1988;56 893-7. (Pubitemid 19008360)
25. Rush AJ, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS) Preliminary findings. Psychiatry Res 1986;18 65-87. (Pubitemid 16085767)
26. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS) Psychometric properties. Psychol Med 1996;26 477-86. (Pubitemid 26142491)
27. Kroenke K, Spitzer RL, Williams JB. The PHQ-9 Validity of a brief depression severity measure. J Gen Intern Med 2001;16 606-13. (Pubitemid 32823891)
28. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR) A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54 573-83. (Pubitemid 37289444)
29. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67 361-70. (Pubitemid 13098606)
30. Dodd S, Williams LJ, Jacka FN, et al. Reliability of the Mood Disorder Questionnaire Comparison with the Structured Clinical Interview for the DSM-IV-TR in a population sample. Aust N Z J Psychiatry 2009;43 526-30.
31. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23 56-62.
32. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134 382-9. (Pubitemid 9136500)
33. Löwe B, Unützer J, Callahan CM, et al. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care 2004;42 1194-201. (Pubitemid 39627296)
34. Agency for Healthcare Research and Quality. Choosing antidepressants for adults Clinician's guide, 2007 (available at http://effectivehealthcare.ahrq. gov/healthInfo.cfm?infotype=sg&DocID=9&ProcessID=7, accessed July 25, 2011).
35. Olfson M, Marcus SC, Tedeschi M, et al. Continuity of anti-depressant treatment for adults with depression in the United States. Am J Psychiatry 2006;163 101-8. (Pubitemid 43050110)
36. Dietrich AJ, Oxman TE, Williams JW Jr, et al. Re-engineering systems for the treatment of depression in primary care Cluster randomised controlled trial. BMJ 2004; 329 602.
37. Glied S, Herzog K, Frank R. The net benefits of depression management in primary care. Med Care Res Rev 2010;7 251-74.
38. Pyne JM, Rost KM, Zhang M, et al. Cost-effectiveness of a primary care depression intervention. J Gen Intern Med 2003;18 432-41. (Pubitemid 36836672)
39. Watkins KE, Burnam MA, Orlando M, et al. The health value and cost of care for major depression. Value Health 2009;12 65-72.
40. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder, 3rd edition, 2010 (available at www.psych.org/guidelines/mdd2010, accessed August 3, 2011).
41. Simon GE. Long-term prognosis of depression in primary care. Bull World Health Organ 2000;78 439-45. (Pubitemid 30367597)
42. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps A STAR*D report. Am J Psychiatry 2006;163 1905-17. (Pubitemid 44807782)
43. Gervasoni N, Weber Rouget B, Miguez M, et al. Perfor-mance of the Mood Disorder Questionnaire (MDQ) according to bipolar subtype and symptom severity. Eur Psychiatry 2009;4 341-4.
44. Hirschfeld RM, Williams JB, Spitzer RL, et al. Develop-ment and validation of a screening instrument for bipolar spectrum disorder The Mood Disorder Questionnaire. Am J Psychiatry 2000;157 1873-5.
45. Feldman MD, Franks P, Duberstein PR, et al. Let's not talk about it Suicide inquiry in primary care. Ann Fam Med 2007;5 412-8. (Pubitemid 47535971)
46. Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide A review of the evidence. Am J Psychiatry 2002;159 909-16. (Pubitemid 34586933)
47. Owens C, Lambert H, Donovan J, et al. A qualitative study of help seeking and primary care consultation prior to suicide. Br J Gen Pract 2005;55 503-9. (Pubitemid 40903794)
48. Agency for Healthcare Research and Quality. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression, 2007 (available at http://effectivehealthcare.ahrq.gov/healthInfo. cfm?infotype=rr&ProcessID=7%20&DocID=61, accessed July 25, 2011).
49. Fochtmann LJ, Gelenberg AG. Guideline watch Practice guideline for the treatment of patients with major depressive disorder, 2nd edition, 2005 (available at www.psychi-atryonline.com/content.aspx?aid=148217, accessed July 25, 2011).
50. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants Background paper for the American College of Physicians. Ann Intern Med 2008;149 734-50.
51. Leon AC, Solomon DA, Mueller TI, et al. A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. Am J Psychiatry 2003;160 727-33. (Pubitemid 41079606)
52. Demyttenaere K, Jaspers L. Review Bupropion and SSRI-induced side effects. J Psychopharmacol 2008; 22 792-804.
53. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder Pharmacokinetic and formulation considerations. Clin Ther 2005;27 1685-95. (Pubitemid 41815222)
54. Sanofi-Aventis US LLC. Aplenzin® (bupropion hydrobro-mide) prescribing information, 2009 (available at http://products.sanofi.us/aplenzin/ aplenzin.pdf, accessed July 25, 2011).
55. Henshall DC, Dürmüller N, White HS, et al. Electro- encephalographic and behavioral convulsant effects of hydrobromide and hydrochloride salts of bupropion in conscious rodents. Neuropsychiatr Dis Treat 2009; 5 189-206.
56. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2009;42 57-90.
57. Eli Lilly and Company. Symbyax® (olanzapine and fluox-etine) prescribing information, 2011 (available at http://pi.lilly.com/us/symbyax-pi. pdf, accessed July 25, 2011).
58. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder A multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68 843-53. (Pubitemid 47015482)
59. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008;4 CD000448.
60. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2009;33 118-27.
61. Caccia S, Gobbi M. St. John's wort components and the brain Uptake, concentrations reached and the mechanisms underlying pharmacological effects. Curr Drug Metab 2009;10 1055-65.
62. Anderson EL, Reti IM. ECT in pregnancy A review of the literature from 1941 to 2007. Psychosom Med 2009;71 235-42.
63. U.K. ECT Review Group. Efficacy and safety of electrocon-vulsive therapy in depressive disorders A systematic review and meta-analysis. Lancet 2003;361 799-808.
64. Dumitriu D, Collins K, Alterman R, et al. Neuro-stimulatory therapeutics in management of treatment-resistant depression with focus on deep brain stimulation. Mt Sinai J Med 2008;75 263-75.
65. Bares M, Kopecek M, Novak T, et al. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression A double-blind, single-centre, randomized study. J Affect Disord 2009;118 94-100.
66. Demitrack MA, Thase ME. Clinical significance of tran-scranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression Synthesis of recent data. Psychopharmacol Bull 2009;42 5-38.
67. Kennedy SH, Milev R, Giacobbe P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT). Clinical guidelines for the management of major depressive disorder in adults IV. Neurostimulation therapies. J Affect Disord 2009;117 S44-S53.
68. Spellman T, Peterchev AV, Lisanby SH. Focal electrically administered seizure therapy A novel form of ECT illustrates the roles of current directionality, polarity, and electrode configuration in seizure induction. Neuro-psycho pharmacology 2009;34 2002-10.
69. Ward HE, Hwynn N, Okun MS. Update on deep brain stimulation for neuropsychiatric disorders. Neurobiol Dis 2010;38 346-53.
70. Even C, Schröder CM, Friedman S, et al. Efficacy of light therapy in nonseasonal depression A systematic review. J Affect Disord 2008;108 11-23. (Pubitemid 351418015)
71. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies Predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008;65 870-80.
72. Simon J, Pilling S, Burbeck R, et al. Treatment options in moderate and severe depression Decision analysis supporting a clinical guideline. Br J Psychiatry 2006;189 494-501. (Pubitemid 44876867)
73. Han MK, Huh Y, Lee SB, et al. Prevalence of stroke and transient ischemic attack in Korean elders Findings from the Korean Longitudinal Study on Health and Aging (KLoSHA). Stroke 2009;40 966-9.
74. Shigemura J, Sato Y, Yoshino A, et al. Patient satisfaction with antidepressants An Internet-based study. J Affect Disord 2008;07 155-60. (Pubitemid 351288929)
75. Weihs KL, Settle EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000;61 196-202. (Pubitemid 30214516)